Atorvastatin is a member of the drug class of statins with total segment sales of $34.37 million in the private sector of Saudi with an average growth rate of 18.9%.

On the other hand, and to compliment Tabuk’s injectable cephalosporin portfolio, Protec®“Cefepime”, a fourth generation cephalosporin was also launched during this month.